OmniAb Deep Dive: Partner Scale Is Real; Royalty Conversion Is Still a Thesis
Business Model and Revenue Architecture
OmniAb does not develop or sell drugs. It licenses a proprietary antibody and binder discovery stack to pharmaceutical companies, biotechnology companies, and a smaller set of academic institutions, then participates economically if those partners advance and commercialize molecules discovered on the platform. The contractual architecture is deliberate. Typical agreements combine upfront or annual access fees, service revenue when OmniAb runs discovery work, success-based milestones across preclinical, intellectual property, clinical, regulatory, and commercial events, and royalties on net sales. Management reports that more than 98% of active programs carry contracted downstream economics, that total contracted potential milestones on the standard antibody license book exceed $3 billion, and that the portfolio-average royalty rate is approximately 3.4%, calculated on a blended basis for tiered structures assuming a $1.3 billion sales level. The royalty term is generally the longer of ten years from first commercial sale or the last relevant patent expiration, and it is typically tied to patents the partner files on the discovered antibody rather than solely to OmniAb’s older platform patents. That structure is designed to lengthen and diversify streams if products ever reach meaningful sales.
The economic logic is that of a capital-light option portfolio. OmniAb funds a relatively fixed technology and breeding infrastructure, hands candidates to partners who bear the vast majority of clinical and commercial spend, and collects a small percentage of success. Incremental gross margin on milestones and royalties is extremely high because there is essentially no cost of goods and no sales force attached to a partner’s product. The offset is that recognized revenue is lumpy, largely outside OmniAb’s control, and has not yet converted into a durable royalty base. Full-year revenue was $34.2 million in 2023, $26.4 million in 2024, and $18.7 million in 2025, with the 2025 decline driven by lower license and milestone revenue and by the wind-down of legacy small-molecule ion channel service work. Royalty revenue itself was only $0.9 million in 2025, up from $0.6 million in 2024. That figure is the cleanest statement of where the model actually stands: the franchise has produced approved products, but those products are not yet a meaningful cash engine.
2026 has interrupted the multi-year revenue decline without changing the underlying dependence on event timing. Second-quarter revenue was $13.4 million versus $3.9 million a year earlier, and first-half revenue was $27.8 million versus $8.1 million, almost entirely on milestone recognition as partner programs moved through defined clinical stages. Management raised full-year 2026 revenue guidance to $32 million to $36 million and reaffirmed that range at the October 6, 2026 Investor and Analyst Day, alongside cash operating expenses of $51 million to $55 million and an expectation of being close to cash-flow breakeven for the year. GAAP operating expense guidance of $84 million to $88 million remains well above revenue because of non-cash charges. The shape of the year is itself a warning. With $27.8 million already recognized in the first half, the second half is guided to be thin. Milestone revenue that arrives early does not create a run-rate.
A second, still small revenue architecture is being bolted onto the license model. xPloration, the high-throughput single B-cell screening system, is sold as an instrument with recurring consumables, software, and service. Management expects $2 million to $3 million of xPloration revenue in 2026, with that line doubling in 2027 and doubling again in 2028. Cash at June 30, 2026 was $52.0 million, and year-end 2026 cash is guided at $37 million to $41 million. The balance sheet can fund the current plan if milestones and the early instrument ramp arrive roughly as guided. It does not fund a multi-year miss.
Technology Portfolio
The core asset is a set of genetically engineered animals whose immune systems generate human-sequence or human-framework antibodies in vivo, which the company describes as Biological Intelligence. OmniRat, launched in 2012, was an early successful knockout of endogenous rat immunoglobulin genes with human transgenes. OmniMouse uses the same transgenes in a more familiar host. OmniChicken, launched in 2016, is a transgenic bird that produces human-sequence repertoires through gene conversion, with diversity concentrated in complementarity-determining regions and frameworks built on conserved human variable-region genes. The evolutionary distance between chickens and mammals is the practical point. Antigens that are poorly immunogenic in rodents often raise a response in birds, which matters for conserved human proteins, multipass membrane targets, and certain complex epitopes.
Format-specific animals sit on top of those hosts. OmniFlic and OmniClic are common-light-chain rat and chicken systems built for bispecific discovery, where pairing and developability are the usual failure modes. OmniTaur contributes cow-inspired structural features aimed at difficult targets. OmnidAb is an in vivo single-domain platform on a human VH scaffold, intended to avoid some of the engineering burden of camelid-derived domains. OmniUltra, launched in December 2025, is a transgenic chicken engineered to display ultralong CDRH3 domains on a human antibody framework, extending the system into mini-proteins, structured peptides, and binders for modalities such as radioligands and chimeric antigen receptor constructs. OmniDeep is the computational layer, a suite of in silico and machine-learning tools used to mine sequence data and optimize candidates. OmniHub is the partner-facing data interface. xPloration is the physical screening layer: cells are isolated into roughly 1.5 million capillaries on a proprietary chip, imaged with automated computer vision, and recovered by laser for sequencing, with the company claiming the ability to pull thousands of hits from a campaign in real time.
Ion channel discovery is a quieter but newly revalidated capability. Service revenue in this area declined as legacy small-molecule programs ended, and the company took a non-cash impairment on related assets in late 2025. In August 2026 OmniAb signed a global collaboration and license with Eli Lilly on an undisclosed ion channel target and modality, with management describing the economics as substantial relative to a typical access deal. That agreement does not restore the old service book by itself, but it is external evidence that large pharma still wants specialized biology that pure sequence-design shops do not automatically replicate.
What OmniAb sells, in practice, is access plus optional hands-on discovery, not a drug product. Partners can run campaigns in their own laboratories or have OmniAb execute them. The product roadmap of the last eighteen months is an attempt to widen the definition of what is licensed: screening hardware, peptide discovery, and ion channel biology, all still attached to the same downstream milestone and royalty logic wherever an antibody or related binder is the output.
Customers, End Markets, and Suppliers
The customer is the drug developer, not the patient. As of June 30, 2026 the company reported 110 active partners and 425 active programs, including 34 programs in clinical development or on the market that still carry economics to OmniAb. At the October investor day management described a base of more than 110 partners. Eight of the ten largest global pharmaceutical companies by 2025 sales are active partners. Headquarters mix at mid-year was roughly 57% United States, 22% Europe, 20% Asia-Pacific, and 1% Middle East. By type, about 75% of partners were discovery-stage companies, 20% commercial-stage companies, and 5% academic. New licenses in 2025 and the first half of 2026 included Dana-Farber Cancer Institute, MabTherix, EnRosa Therapeutics, argenx, Eli Lilly, and additional undisclosed large pharmaceutical companies. The installed base is broad. The cash-flow concentration is not.
End demand is the antibody therapeutics market, which industry estimates placed near $291 billion in 2025 and about $311 billion in 2026, with a projected path toward roughly $597 billion by 2035 at a mid-single-digit to high-single-digit growth rate, driven by oncology, immunology, and the expansion of bispecifics, antibody-drug conjugates, and other engineered formats. OmniAb’s direct market is narrower: the tools, animals, and services used to discover those molecules. Published estimates for monoclonal antibody discovery platforms vary with definition, from roughly $1 billion on a tight platform definition to the mid-single-digit billions when services and computational tools are included, with forecast growth rates in a high-single-digit to low-double-digit range. Phage display has historically held the largest technology share, often cited around a quarter to 30% of platform spending, while computational methods are the fastest-growing slice. OmniAb’s $19 million to $36 million revenue range is a low-single-digit share, at best, of the broad discovery-services market. Its relevance is higher inside the licensed transgenic-animal niche, where repeat use by a majority of the global top ten is a better indicator than revenue share of a loosely defined category.
The commercial products that do carry residual economics are geographically constrained. Zimberelimab, an OmniRat-derived PD-1 antibody, is approved in China in relapsed or refractory classical Hodgkin lymphoma and cervical cancer, with Gloria Biosciences, Arcus Biosciences, and Gilead involved across territories and combinations. Sugemalimab, an OmniRat-derived PD-L1 antibody originated at CStone, is approved in China across several tumor types and holds European and UK approval in first-line metastatic non-small cell lung cancer in combination with chemotherapy. CStone’s 2025 commercialization arrangement with Istituto Gentili covers Western Europe and the UK and includes a near-50% share of net sales recognized by CStone as supply and related revenue, not a clean royalty pass-through to OmniAb. China reimbursement dynamics, not U.S. list prices, dominate current sales. That is why royalties can rise modestly, as they did in 2025, and still remain under $1 million. Teclistamab, the Johnson & Johnson BCMA CD3 bispecific marketed as TECVAYLI, is OmniRat-derived, but launch milestones were paid and the company excludes it from programs with remaining economics. The same exclusion applies to tiragolumab, etentamig, and surovatamig. Historical scientific success and current economic exposure are not the same thing.
The programs that matter for the next several years are partner-funded and still pre-commercial. Management has pointed to approximately $340 million of remaining contracted milestone potential on the clinical and approved book as of June 30, 2026, and has said partners have committed or are spending more than $2.4 billion to advance OmniAb-derived clinical programs. Highlighted assets include Johnson & Johnson’s ramantamig in multiple myeloma, which moved toward Phase 3 in 2026; Merck KGaA’s precemtabart tocentecan, a CEACAM5-directed antibody-drug conjugate; Immunovant and Hanall’s IMVT-1402, an FcRn antibody in multiple autoimmune indications; and Teva’s TEV-408, which management has described as having multi-indication potential. On September 23, 2026 Immunovant discontinued IMVT-1402 in cutaneous lupus erythematosus after a proof-of-concept study missed its primary endpoint, while continuing Graves disease, difficult-to-treat rheumatoid arthritis, generalized myasthenia gravis, CIDP, and Sjögren’s disease, with potentially registrational readouts in Graves and myasthenia gravis expected in 2027. That sequence is the business model in miniature. OmniAb does not choose the indication, does not run the trial, and absorbs the economic consequence of a partner’s portfolio decision.
Supplier dependence is secondary to intellectual property dependence. The scarce inputs are breeding colonies of engineered animals, proprietary screening chips and consumables, and specialized ion channel biology, not commodity reagents. Peptide manufacturing under the new OmniTides offering is intended to be performed by qualified contract organizations rather than built as internal capacity. Historical ion channel work and some early antibody campaigns used external discovery partners, including firms that now compete in adjacent services. There is no single supplier whose interruption would look like a manufacturing-scale single-source risk at a conventional biopharma company. The operational risk is biological and contractual: colony health, technology performance on a given target, and partner willingness to start the next campaign.
Competitive Position
The discovery market is fragmented by technology philosophy rather than by a single share leader that OmniAb can be ranked against cleanly. In vivo transgenic systems compete with phage and yeast display, hybridoma and B-cell recovery methods, synthetic DNA libraries, and, increasingly, generative protein design. OmniAb’s own filings name the relevant set directly. On engineered-animal and related discovery, the company cites AbCellera, Ablexis, Alloy Therapeutics, Biocytogen, Nona Biosciences, Leveragen, Regeneron, and Twist Bioscience. On single-cell screening it cites AbCellera, Bruker, Sartorius, and smaller instrument specialists. On ion channels it cites Charles River, Evotec, Metrion Biosciences, and WuXi AppTec. Regeneron is the scientific benchmark and not a commercial licensor; its VelocImmune platform is used internally and selectively, which removes the most validated transgenic franchise from the license market OmniAb actually contests.
Among companies that do sell access, the competitive set has diverged in strategy. AbCellera built a microfluidic and data-science discovery engine, signed a wide partner book, and then redirected capital toward an internal clinical pipeline, including a non-hormonal NK3R antibody that produced Phase 2 data in 2026. AbCellera’s 2025 revenue of about $75 million included a large litigation settlement and is not a clean platform comparison, and 2026 platform revenue has been modest outside of sizeable upfronts on T-cell engager collaborations, including a Jazz Pharmaceuticals deal with $56 million upfront for the first two programs. Alloy Therapeutics has pursued the opposite posture: non-exclusive, relatively frictionless access to multiple mouse strains, plus expansion into genetic medicines and generative design, including an April 2026 multi-target antisense collaboration with Biogen. Biocytogen, operating from China, has scaled RenMice platforms and an automated discovery workstation, has cited on the order of 450 partnerships and roughly 30 partner clinical programs sourced from its antibodies, and continues to out-license bispecific and antibody-drug conjugate candidates, including a July 2026 multi-asset arrangement with Whitehawk. Adimab remains the established private yeast-display alternative, particularly where partners want a synthetic human repertoire without animal work.
OmniAb’s observable position is a wide but shallow license franchise. One hundred ten partners and 425 programs, with eight of the global top ten inside the tent, is a real distribution advantage against any single emerging platform. It is not pricing power, and it is not a demonstrated royalty annuity. Program attrition is normal and material: 40 programs were terminated in 2025 against 84 starts, for a net addition of 44. The company is winning campaigns often enough to grow the book. It is not winning them in a way that has yet shown up in commercial royalties. No credible public source assigns OmniAb a stable percentage of transgenic-animal discovery spend. The honest statement is that it is one of a small number of scaled licensors, differentiated by host diversity rather than by being the default system at every large pharma company.
Sources of Advantage
The most durable advantage is host diversity that is expensive and slow to copy. OmniAb is unusual in offering transgenic mouse, rat, and chicken systems, plus cow-inspired architecture, common-light-chain animals, a human-framework single-domain system, and, since late 2025, an ultralong-CDRH3 chicken. Partners that fail on a target in one species can move to another without leaving the contract framework. Chicken immunogenicity against conserved mammalian proteins is a specific, repeatedly cited reason large companies keep the platform, not a marketing abstraction. Common-light-chain animals address a structural industry problem as bispecific and multispecific formats take a larger share of new antibody starts. In vivo affinity maturation also produces sequence data with developability characteristics that pure in silico libraries still struggle to guarantee on the first cycle, which is why computational tools at OmniAb are positioned as a complement to biological repertoires rather than a replacement.
A second advantage is the structure of the royalty itself. Because duration is generally linked to the partner’s product patents, a successful antibody can throw off cash for longer than the life of the original animal patents alone. Stacking works in OmniAb’s favor if, and only if, several products reach sales. Three percent of a $1 billion product is $30 million of nearly pure margin. Three such products would transform the income statement of a company that today does about that much in total revenue. The contracted book, with 98% of programs carrying downstream economics, is the inventory of those options. It is not evidence that the options will finish in the money.
Operating leverage is real and already visible. The company employs about 89 people. Cash operating expense is guided in the low-to-mid $50 million range while the partner and program counts have continued to rise. GAAP operating expense fell from about $101 million in 2024 to $87.6 million in 2025 even as net loss remained large at $64.8 million. Milestone and royalty dollars, when they arrive, do not require proportional headcount. The second-quarter 2026 result illustrated the point: revenue rose sharply and operating expense did not. That is the correct way to run this model. It also means the equity story is almost entirely about the numerator of partner success, not about OmniAb finding another ten points of cost efficiency.
Distribution and information are softer advantages that still matter. A partner base that includes most of the global top ten, plus a growing Asia-Pacific cohort, gives the company an early read on which formats, epitopes, and modalities sponsors are actually funding. That feedback loop has shaped OmnidAb, OmniUltra, xPloration, and the Lilly ion channel collaboration. It does not prevent a competitor with a cheaper mouse or a faster AI cycle from taking the next campaign. Intellectual property is a supporting, not dominating, advantage: the company reports a portfolio that includes 29 issued U.S. patents directed to the animals and related inventions, with counterparts in Europe, Japan, and China, built in part through the 2016 acquisition of OMT and the 2017 acquisition of Crystal Bioscience. Platform patents age. Partner product patents are the more important clock.
Industry Dynamics, Opportunities, and Threats
The industry backdrop is favorable to the existence of the business and unfavorable to any assumption that today’s platform mix is permanent. Antibody therapeutics continue to gain share of global drug sales. Complex formats, including bispecifics, antibody-drug conjugates, radioligand binders, and cell-therapy targeting domains, raise the technical bar for discovery and therefore the willingness of sponsors to pay for specialized systems. Peptides have also re-entered the commercial conversation, accounting for about 10% of FDA approvals between 2020 and 2024, with management citing an addressable peptide therapeutics market of roughly $117 billion in 2026 and a path above $300 billion by the mid-2030s. Automation and data generation are becoming standard requirements rather than differentiators, which is the opening for xPloration. Artificial intelligence adoption at partners is a tailwind for any company that can feed models with large, well-annotated biological datasets, and a headwind for any company whose only product is an animal.
The opportunity set that can actually move OmniAb’s numbers in the next two to four years is narrower than the technology narrative. Management sees potential primary completion of as many as 19 clinical trials of OmniAb-derived drugs in the remainder of 2026 and in 2027. The nearer cash is the roughly $340 million of remaining contracted milestones on the existing clinical book, not the $3 billion headline, which is heavily weighted to events that statistically will not all occur. A launch of IMVT-1402 in an initial indication, if the 2027 registrational studies succeed, and continued late-stage progress for ramantamig and precemtabart tocentecan are the clearest paths to royalties that would register on the income statement. Geographic expansion of sugemalimab in Europe is a smaller, more certain increment and should not be modeled as a U.S.-style PD-L1 franchise. xPloration, if the doubling path holds, becomes a mid-single-digit million revenue line by 2028 and a relationship tool well before it becomes a profit center. Ion channel work with Lilly can reopen a service category that had been shrinking.
The threats are equally specific. Clinical and portfolio risk sits entirely with customers. The September 2026 discontinuation of IMVT-1402 in cutaneous lupus is a current example, not a theoretical one, and it follows a broader pattern in which OmniAb-derived molecules in crowded mechanisms, including TIGIT, have failed or been deprioritized without leaving residual economics. Partner attrition of dozens of programs per year is structural. Milestone timing created a strong first half of 2026 and a guided weak second half; the same pattern can reverse and produce a year that looks like 2025. Cash of $37 million to $41 million at the end of 2026 is adequate for a breakeven plan and inadequate for a stalled 2027. Royalty acquirers have approached the company about buying slices of specific streams. Management has declined, which preserves upside and also preserves dilution risk if the clinical book slips.
Competition is intensifying from two directions at once. Scaled licensors with lower access friction, particularly Alloy and Biocytogen, can win price-sensitive or China-centered campaigns. Generative design platforms can win campaigns where the epitope is known and the problem is affinity, specificity, and developability rather than the initial immune response. OmniAb’s chicken systems are most defensible where immunization itself is the bottleneck. They are least defensible where a partner already has a clinical antibody and wants fifty optimized variants in six weeks. China pricing on the two marketed antibodies with residual economics caps near-term royalty magnitude even if volumes grow through reimbursement lists. Intellectual property challenges, biosimilar pressure on the older PD-1 and PD-L1 products, and any broad shift by large pharma toward captive transgenic colonies would all hit the license model before they hit an internal pipeline company, because OmniAb has no wholly owned drug to fall back on.
New Platforms as Growth Drivers
Three initiatives are far enough along to be treated as operating plans rather than science projects. xPloration moved from a 2025 partner access program to general commercial availability in October 2026. The system is aimed at a B-cell screening market the company sizes above $500 million and describes as growing at a double-digit rate. Commissioned market research cited by management found that 63% of respondents expected to need a new screening platform within three years and that more than 80% would definitely or probably buy the preferred xPloration configuration. Those figures are vendor research and should be discounted, but the product logic is sound: instrument revenue plus high-margin consumables, sold into a partner base that already trusts the animals, with a secondary benefit of generating sequence data for OmniDeep. The financial ambition is still small. Two to three million dollars in 2026, doubling twice, is roughly $8 million to $12 million by 2028 if execution is clean. That is meaningful relative to a $20 million historical revenue base and immaterial relative to the $3 billion milestone story. The strategic value is stickiness. A partner that owns the instrument is more likely to start the next OmniAb campaign on site.
OmniUltra and OmniTides are the attempt to enter peptide and mini-protein discovery without abandoning the animal franchise. OmniUltra places ultralong CDRH3 diversity on a human framework inside a chicken, which the company argues can yield naturally optimized structured peptides and unusual paratopes for targets that conventional immunoglobulin formats handle poorly. OmniTides, introduced at the October 2026 investor day, packages that biology into a discovery-to-synthesis workflow, with chemical manufacture available through qualified contract organizations. The commercial logic is that peptide therapeutics are a large and growing end market, that metabolic, oncology, and neurological applications are expanding the set of sponsors who will pay for peptide discovery, and that an in vivo optimization step is a differentiator versus purely synthetic peptide libraries. There is no disclosed OmniTides revenue, no disclosed number of peptide campaigns, and no partner yet named as a lead user of the branded offering. It should be treated as a 2027 and 2028 business-development opportunity, not as a 2026 earnings driver. If it works, it expands the definition of a licensable OmniAb program into a modality where royalties and milestones can be structured similarly to antibodies. If sponsors conclude that display or generative chemistry is faster, it remains a technology slide.
The quieter growth driver is the maturation of technologies launched earlier. Six clinical programs are now derived from the chicken platforms, including OmnidAb, which is evidence that the newer animals are not stuck in perpetual evaluation. The Lilly ion channel collaboration is evidence that a capability the market had written down can still attract a top-tier sponsor when the target is hard. None of these items replaces the need for one or two large partner launches. They do reduce the probability that the company is a single-technology story if the classic rodent campaigns slow.
Credible Competitive Entrants
The entrants that matter are funded, partnered, and already in or adjacent to the workflows OmniAb sells. They are not university methods. Alloy Therapeutics has moved from a mouse-access company into an ecosystem vendor spanning antibodies, multispecifics, antisense oligonucleotides, and generative redesign, with named large-pharma relationships including Biogen. Its pitch is speed and non-exclusivity. A campaign that produces qualified leads in roughly four months, or a generative redesign cycle measured in weeks, competes directly for the same discovery budget OmniAb is asking partners to commit to an immunization campaign. Biocytogen has the scale, the China cost position, the partner count, and enough clinical out-licensing activity to be treated as an incumbent challenger rather than a new entrant, but its automation and AI workstation investments are closing the historical gap in throughput that Western transgenic licensors once assumed they owned.
On the computational side, BigHat Biosciences is the clearest recent example of an AI-native protein company that has crossed into the clinic and into repeat pharma work. It closed a $75 million Series C in September 2026, bringing total funding to about $223 million, has collaborations with Amgen, Merck, Johnson & Johnson, AbbVie, and Eli Lilly, and dosed the first patient in July 2026 on BHB810, a CDH17 antibody-drug conjugate. Absci has delivered functional AI-designed antibody leads under a dermatology collaboration with Almirall that carries up to $650 million in potential milestones and royalties, and has expanded that collaboration to a second target. These companies are not replacing transgenic animals across the board. They are taking the subset of problems where design, developability, and cycle time dominate, and they are signing the same class of sponsor OmniAb needs in order to keep adding programs. AbCellera’s continued shift toward internal assets and high-value T-cell engager partnerships is a different kind of pressure: it removes a pure-play platform comparable and raises the upfront checks that sophisticated partners now expect when the technology claim is differentiation on hard formats. OmniAb’s response has been to stay capital-light and to add hardware and peptide workflows. That is coherent. It is also a bet that partners will keep paying for biological diversity after they have in-house generative tools.
Management Track Record
Matthew Foehr has been chief executive since the November 2022 separation from Ligand Pharmaceuticals, where he was president and chief operating officer from 2011 to 2022. The Ligand pedigree is relevant. That company built a public-market franchise on milestones and royalties rather than on wholly owned development risk, which is the template OmniAb is trying to run in pure form. Foehr has also sat on the Viking Therapeutics board since 2014. Kurt Gustafson has been chief financial officer since March 2022, with prior CFO roles at Spectrum Pharmaceuticals and Halozyme and a long Amgen finance career that included treasury and the finance leadership of Amgen International. He remains a director of Xencor. In 2026 the company appointed Amechi Nwachuku as executive vice president and chief operating officer with responsibility for xPloration strategy and operations, which is the correct organizational signal if the instrument business is meant to be sold rather than demonstrated.
The operating record since the spin-off is mixed and should be described that way. Partner count rose from 77 in 2023 to 91 in 2024, 107 at the end of 2025, and 110 by mid-2026. Active programs rose from 325 to 363 to 407 to 425 over the same span, net of substantial attrition. Newer technologies have entered the clinic. OmniUltra launched on the timeline management had set. xPloration moved from internal tool to partner access to open commercial sale within roughly eighteen months. Guidance for 2026 was raised twice on actual milestone events, not on a change in narrative. Headcount and cash operating expense were brought down, including a 2025 reduction of about 22 roles, and the company is guiding to something close to cash-flow breakeven without a dilutive equity raise in the current year. Inbound interest from royalty buyers was disclosed and declined. That is disciplined if management’s view of the streams is correct.
The misses are not cosmetic. Revenue fell for three consecutive years through 2025. Royalty revenue never left the sub-$1 million range even after multiple product approvals. High-profile molecules discovered on the platform either failed clinically or left no residual economics, so the scientific résumé overstates the economic résumé. The 2026 rebound is front-loaded and milestone-driven, which is exactly the volatility the model was supposed to outgrow. Governance scores are not a strength; Institutional Shareholder Services assigned a quality score of 9 as of October 1, 2026, with a particularly weak board pillar. A company this small, with this much of its value in contracts and colonies rather than in a commercial product, is unusually dependent on a handful of executives staying, allocating limited cash to the right technology, and resisting the temptation either to build an internal pipeline or to sell the royalty book too early. So far they have resisted both. The next test is whether 2027 guidance, which management intends to give with fourth-quarter results in late February or early March 2027, shows royalty and instrument revenue beginning to replace milestone luck.
The Scorecard
OmniAb is a scaled discovery licensor with a genuinely differentiated animal portfolio, a partner list that includes eight of the ten largest pharmaceutical companies, 425 active programs, more than $3 billion of contracted milestone potential, and an average royalty near 3.4% on a book where nearly every program has downstream economics. The organization is lean enough that milestones fall through to a sharply narrower loss, cash burn is being brought toward breakeven, and new offerings in screening hardware, ultralong-CDRH3 biology, peptides, and ion channels are real enough to have launch dates, a Lilly contract, and a stated revenue path. That is a better strategic position than the 2023 to 2025 income statement suggested.
It is not yet a royalty company. Commercial royalties were $0.9 million in 2025. The two approved products that still pay are China-centered immunotherapies in crowded classes. Several historically important OmniAb-derived drugs carry no remaining economics. The clinical options that could change the model, including IMVT-1402, ramantamig, and precemtabart tocentecan, are partner-controlled, indication-specific, and already showing attrition, as the September 2026 cutaneous lupus discontinuation demonstrated. xPloration and OmniTides can diversify revenue, but from a base of a few million dollars. Competitive pressure from non-exclusive transgenic licensors and from funded AI-native design companies is aimed at the same sponsors. The investment case is an option on partner conversion inside a fixed-cost wrapper, not a demonstrated compounding franchise. Until at least one large partner product produces a visible, recurring royalty, the contracted backlog should be treated as inventory, not as earnings power.